{"filing":{"accession_number":"0001193125-26-342495","cik":"0000728387","ticker":"CATX","company_name":"Perspective Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"catx-20260810.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/728387/000119312526342495/catx-20260810.htm"},"events":[{"id":26656,"run_id":24231,"accession_number":"0001193125-26-342495","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Perspective Therapeutics disclosed Q2 2026 financial results for the quarter ended June 30, 2026, reporting a net loss of $26.8 million ($0.22 per share), R\u0026D expenses of $21.5 million, G\u0026A expenses of $7.8 million, and a cash position of $237 million. The disclosure includes condensed consolidated financial statements and business highlights with clinical program updates.","company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27853,"accession_number":"0001193125-26-342495","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses quarterly financial results for Q2 2026 (quarter ended June 30, 2026) via a press release furnished as Exhibit 99.1. The press release reports net loss of $26.8 million ($0.22 per share), R\u0026D expenses of $21.5 million, G\u0026A expenses of $7.8 million, and cash position of $237 million as of June 30, 2026. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and operational performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:36:36.564329+00:00","company_name":"","ticker":null,"filing_date":""},{"id":27854,"accession_number":"0001193125-26-342495","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The Item 8.01 disclosure centers on the company posting an updated corporate presentation to its website. However, the supplemental exhibits (EX-99.1 and EX-99.2) reveal that the filing includes a press release announcing \"2Q 2026 Results\" with detailed financial statements (condensed consolidated balance sheets and statements of operations) for the quarter ended June 30, 2026, along with business highlights and clinical program updates. The financial results show net loss of $26.8 million for Q2 2026 and cash position of $237 million as of June 30, 2026. This constitutes a quarterly earnings release, which is material to investors assessing the registrant's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:36:36.564329+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27853,"accession_number":"0001193125-26-342495","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses quarterly financial results for Q2 2026 (quarter ended June 30, 2026) via a press release furnished as Exhibit 99.1. The press release reports net loss of $26.8 million ($0.22 per share), R\u0026D expenses of $21.5 million, G\u0026A expenses of $7.8 million, and cash position of $237 million as of June 30, 2026. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and operational performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:36:36.564329+00:00","company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","filing_date":"2026-08-10"},{"id":27854,"accession_number":"0001193125-26-342495","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The Item 8.01 disclosure centers on the company posting an updated corporate presentation to its website. However, the supplemental exhibits (EX-99.1 and EX-99.2) reveal that the filing includes a press release announcing \"2Q 2026 Results\" with detailed financial statements (condensed consolidated balance sheets and statements of operations) for the quarter ended June 30, 2026, along with business highlights and clinical program updates. The financial results show net loss of $26.8 million for Q2 2026 and cash position of $237 million as of June 30, 2026. This constitutes a quarterly earnings release, which is material to investors assessing the registrant's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:36:36.564329+00:00","company_name":"Perspective Therapeutics, Inc.","ticker":"CATX","filing_date":"2026-08-10"}]}